Evaluation of self-reported progression and correlation of imatinib dose to survival in patients with metastatic gastrointestinal stromal tumors: An open cohort study

Journal of Gastrointestinal Cancer

Volumn 41, Issue 1, 2010, Pages 60-70

  Call, Jerry ^a   Scherzer, Norman J ^a   Josephy, P David ^b   Walentas, Christopher ^c  

^a Life Raft Group   (United States)

^b UNIVERSITY OF GUELPH   (Canada)

^c NONE   (United States)

Author keywords

Gastrointestinal stromal tumor; GIST; Imatinib; Open cohort study; Overall survival; Self reported progression free survival

Indexed keywords

IMATINIB; STEM CELL FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER LOCALIZATION; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUESTIONNAIRE; SELF REPORT; SEX DIFFERENCE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COHORT STUDIES; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; QUESTIONNAIRES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77950187284     PISSN: 19416628     EISSN: 19416636     Source Type: Journal    
DOI: 10.1007/s12029-009-9111-x     Document Type: Article

References (38)

1. C Mucciarini G Rossi F Bertolini R Valli C Cirilli I Rashid L Marcheselli G Luppi M Federico 2007 Incidence and clinicopathologic features of gastrointestinal stromal tumors. A population-based study BMC Cancer 7 230 10.1186/1471-2407-7-230 18096058
2. WG Goettsch SD Bos N Breekveldt-Postma M Casparie RM Herings PC Hogendoorn 2005 Incidence of gastrointestinal stromal tumours is underestimated: results of a nation-wide study Eur J Cancer 41 2868 2872 10.1016/j.ejca.2005. 09.009 16293410 (Pubitemid 41713125)
3. P Reddy K Boci C Charbonneau 2007 The epidemiologic, health-related quality of life, and economic burden of gastrointestinal stromal tumours J Clin Pharm Ther 32 557 565 10.1111/j.1365-2710.2007.00852.x 1:STN:280: DC%2BD2snosl2jsA%3D%3D 18021332 (Pubitemid 350135105)
4. S Hirota K Isozaki Y Moriyama K Hashimoto T Nishida S Ishiguro K Kawano M Hanada A Kurata M Takeda, et al. 1998 Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors Science 279 577 580 10.1126/science.279. 5350.577 1:CAS:528:DyaK1cXotVyhsw%3D%3D 9438854 (Pubitemid 28067289)
5. Y Kitamura S Hirota T Nishida 2003 Gastrointestinal stromal tumors (GIST): a model for molecule-based diagnosis and treatment of solid tumors Cancer Sci 94 315 320 10.1111/j.1349-7006.2003.tb01439.x 1:CAS:528: DC%2BD3sXkslCnsro%3D 12824897 (Pubitemid 36626361)
6. MC Heinrich CL Corless A Duensing L McGreevey CJ Chen N Joseph S Singer DJ Griffith A Haley A Town, et al. 2003 PDGFRA activating mutations in gastrointestinal stromal tumors Science 299 708 710 10.1126/science.1079666 1:CAS:528:DC%2BD3sXntFWitQ%3D%3D 12522257 (Pubitemid 36159485)
7. JA Fletcher BP Rubin 2007 KIT mutations in GIST Curr Opin Genet Dev 17 3 7 10.1016/j.gde.2006.12.010 1:CAS:528:DC%2BD2sXnslOgug%3D%3D 17208434 (Pubitemid 46109300)
8. GJ Burkill M Badran O Al-Muderis J Meirion Thomas IR Judson C Fisher EC Moskovic 2003 Malignant gastrointestinal stromal tumor: distribution, imaging features, and pattern of metastatic spread Radiology 226 527 532 10.1148/radiol.2262011880 12563150 (Pubitemid 36313445)
9. RP Dematteo MC Heinrich WM El-Rifai G Demetri 2002 Clinical management of gastrointestinal stromal tumors: before and after STI-571 Hum Pathol 33 466 477 10.1053/hupa.2002.124122 1:CAS:528:DC%2BD38XlslCls7o%3D 12094371 (Pubitemid 34747865)
10. JS Gold SM van der Zwan M Gonen RG Maki S Singer MF Brennan CR Antonescu RP De Matteo 2007 Outcome of metastatic GIST in the era before tyrosine kinase inhibitors Ann Surg Oncol 14 134 142 10.1245/s10434-006-9177-7 17080234
11. BJ Druker S Tamura E Buchdunger S Ohno GM Segal S Fanning J Zimmermann NB Lydon 1996 Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells Nat Med 2 561 566 10.1038/nm0596-561 1:CAS:528:DyaK28Xislyhs70%3D 8616716 (Pubitemid 26151518)
12. E Buchdunger CL Cioffi N Law D Stover S Ohno-Jones BJ Druker NB Lydon 2000 Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors J Pharmacol Exp Ther 295 139 145 1:CAS:528:DC%2BD3cXnt1ygur4%3D 10991971
13. CD Mol DR Dougan TR Schneider RJ Skene ML Kraus DN Scheibe GP Snell H Zou BC Sang KP Wilson 2004 Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase J Biol Chem 279 31655 31663 10.1074/jbc.M403319200 1:CAS:528:DC%2BD2cXlslOrtrc%3D 15123710 (Pubitemid 39037836)
14. H Joensuu PJ Roberts M Sarlomo-Rikala LC Andersson P Tervahartiala D Tuveson S Silberman R Capdeville S Dimitrijevic B Druker GD Demetri 2001 Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor N Engl J Med 344 1052 1056 10.1056/ NEJM200104053441404 1:STN:280:DC%2BD3M3gvVekuw%3D%3D 11287975 (Pubitemid 32267975)
15. PA Cassier A Dufresne S Arifi H El Sayadi I Labidi I Ray-Coquard S Tabone P Meeus D Ranchere MP Sunyach, et al. 2008 Imatinib mesilate for the treatment of gastrointestinal stromal tumour Expert Opin Pharmacother 9 1211 1222 10.1517/14656566.9.7.1211 1:CAS:528:DC%2BD1cXkvVemtrw%3D 18422477
16. ID Schnadig CD Blanke 2006 Gastrointestinal stromal tumors: imatinib and beyond Curr Treat Options in Oncol 7 427 437 10.1007/s11864-006-0018-5
17. J Siehl E Thiel 2007 C-kit, GIST, and imatinib Recent Results Cancer Res 176 145 151 10.1007/978-3-540-46091-6-12 1:CAS:528:DC%2BD2sXpsleisLY%3D 17607922
18. F Guilhot 2004 Indications for imatinib mesylate therapy and clinical management Oncologist 9 271 281 10.1634/theoncologist.9-3-271 1:CAS:528:DC%2BD2cXlsFKqurc%3D 15169982 (Pubitemid 38756876)
19. A Hoeben P Schoffski M Debiec-Rychter 2008 Clinical implications of mutational analysis in gastrointestinal stromal tumours Br J Cancer 98 684 688 10.1038/sj.bjc.6604217 1:CAS:528:DC%2BD1cXitVGhtL8%3D 18253129
20. TA Carter LM Wodicka NP Shah AM Velasco MA Fabian DK Treiber ZV Milanov CE Atteridge WH Biggs 3rd PT Edeen, et al. 2005 Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases Proc Natl Acad Sci U S A 102 11011 11016 10.1073/pnas.0504952102 1:CAS:528:DC%2BD2MXnvVWjurg%3D 16046538 (Pubitemid 41105984)
21. MC Heinrich CL Corless GD Demetri CD Blanke M von Mehren H Joensuu LS McGreevey CJ Chen AD Van den Abbeele BJ Druker, et al. 2003 Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor J Clin Oncol 21 4342 4349 10.1200/JCO.2003.04.190 1:CAS:528:DC%2BD2cXpsVWqu7Y%3D 14645423 (Pubitemid 46621810)
22. M Van Glabbeke J Verweij PG Casali A Le Cesne P Hohenberger I Ray-Coquard M Schlemmer AT van Oosterom D Goldstein R Sciot, et al. 2005 Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European organisation for research and treatment of cancer-Italian sarcoma group-Australasian gastrointestinal trials group study J Clin Oncol 23 5795 5804 10.1200/JCO.2005.11.601 16110036 (Pubitemid 46300176)
23. J Desai S Shankar MC Heinrich JA Fletcher CD Fletcher J Manola JA Morgan CL Corless S George K Tuncali, et al. 2007 Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors Clin Cancer Res 13 5398 5405 10.1158/1078-0432.CCR-06-0858 1:CAS:528:DC%2BD2sXhtVCitLzP 17875769 (Pubitemid 47510366)
24. AT van Oosterom I Judson J Verweij S Stroobants E Donato di Paola S Dimitrijevic M Martens A Webb R Sciot M Van Glabbeke, et al. 2001 Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study Lancet 358 1421 1423 10.1016/S0140-6736(01)06535-7 11705489 (Pubitemid 33055745)
25. CD Blanke GD Demetri M von Mehren MC Heinrich B Eisenberg JA Fletcher CL Corless CD Fletcher PJ Roberts D Heinz, et al. 2008 Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT J Clin Oncol 26 620 625 10.1200/JCO.2007.13.4403 1:CAS:528:DC%2BD1cXis1alsL0%3D 18235121
26. CD Blanke C Rankin GD Demetri CW Ryan M von Mehren RS Benjamin AK Raymond VH Bramwell LH Baker RG Maki, et al. 2008 Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033 J Clin Oncol 26 626 632 10.1200/JCO.2007.13.4452 1:CAS:528:DC%2BD1cXis1alsLs%3D 18235122
27. J Verweij PG Casali J Zalcberg A LeCesne P Reichardt JY Blay R Issels A van Oosterom PC Hogendoorn M Van Glabbeke, et al. 2004 Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial Lancet 364 1127 1134 10.1016/S0140-6736(04)17098-0 1:CAS:528: DC%2BD2cXnvVOiu7o%3D 15451219 (Pubitemid 39296599)
28. Feng, W., Henk, H., Thomas, S., Baladi, J., Hatfield, A., Goldberg, G.A., Cortes J. (2006). Compliance and persistency with imatinib. Journal of Clinical Oncology (ASCO Annual Meeting), 24:6038.
29. Van Glabbeke MM, Owzar K, Rankin C, Simes J, Crowley J, GIST Meta-analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST): a meta-analysis based on 1,640 patients (pts). Journal of Clinical Oncology (2007 ASCO Annual Meeting ), 2007. p. 10004.
30. S Patel JR Zalcberg 2008 Optimizing the dose of imatinib for treatment of gastrointestinal stromal tumours: lessons from the phase 3 trials Eur J Cancer 44 501 509 10.1016/j.ejca.2007.11.021 1:CAS:528:DC%2BD1cXjtlWisr0%3D 18234488
31. GD Demetri RS Benjamin CD Blanke JY Blay P Casali H Choi CL Corless M Debiec-Rychter RP DeMatteo DS Ettinger, et al. 2007 NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)-update of the NCCN clinical practice guidelines J Natl Compr Canc Netw 5 Suppl 2 S1 29 17624289 quiz S30
32. Barckett P, Call J, Josephy PD, Scherzer NJ, Singleton R. Disease progression in patients with metastatic gastrointestinal stromal tumor (GIST) receiving Gleevec (imatinib): the effect of drug dosage. In: Connective Tissue Oncology Society 10th Annual Meeting, 2004. p. 227.
33. C Delbaldo E Chatelut M Re A Deroussent S Seronie-Vivien A Jambu P Berthaud A Le Cesne JY Blay G Vassal 2006 Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors Clin Cancer Res 12 6073 6078 10.1158/1078-0432.CCR-05-2596 1:CAS:528:DC%2BD28XhtFWhsbnO 17062683
34. N Widmer LA Decosterd C Csajka S Leyvraz MA Duchosal A Rosselet B Rochat CB Eap H Henry J Biollaz T Buclin 2006 Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein Br J Clin Pharmacol 62 97 112 10.1111/j.1365-2125.2006.02719.x 1:CAS:528:DC%2BD28XoslKnsL4%3D 16842382
35. Demetri GD, Wang Y, Wehrle E, Blanke C, Joensuu H, von Mehren M. Correlation of imatinib plasma levels with clinical benefit in patients (Pts) with unresectable/metastatic gastrointestinal stromal tumors (GIST). In: Gastrointestinal Cancers Symposium, 2008. p. 3.
36. I Judson P Ma B Peng J Verweij A Racine ED di Paola M van Glabbeke S Dimitrijevic M Scurr H Dumez A van Oosterom 2005 Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group Cancer Chemother Pharmacol 55 379 386 10.1007/s00280-004-0876-0 1:CAS:528: DC%2BD2MXhsV2iurw%3D 15592836 (Pubitemid 40379262)
37. H Burger K Nooter 2004 Pharmacokinetic resistance to imatinib mesylate: role of the ABC drug pumps ABCG2 (BCRP) and ABCB1 (MDR1) in the oral bioavailability of imatinib Cell Cycle 3 1502 1505 1:CAS:528: DC%2BD28XjtVersLg%3D 15611623
38. M Debiec-Rychter R Sciot A Le Cesne M Schlemmer P Hohenberger AT van Oosterom JY Blay S Leyvraz M Stul PG Casali, et al. 2006 KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours Eur J Cancer 42 1093 1103 10.1016/j.ejca.2006.01.030 1:CAS:528:DC%2BD28Xks1ertb0%3D 16624552 (Pubitemid 44275331)